Optimal Response in a Patient With CML Expressing <i>BCR–ABL1</i> E6A2 Fusion Transcript With Nilotinib Therapy: A Case Report

The use of primers recognizing more distant exons from the common BCR-ABL1 breakpoint region correctly identified the atypical BCR-ABL1 e16a2 fusion transcript. Treatment with second-generation tyrosine kinase inhibitor nilotinib was effective in this patient expressing the atypical e6a2 BCR-ABL1 fusion transcript.